Beyond Basal Insulin in Type 2 Diabetes

Conference | <b>ADA</b>

Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.

Several studies presented at the 2016 American Diabetes Association annual meeting dealt with going beyond basal insulin treatments for type 2 diabetes mellitus (DM) patients. Here are the highlights from four abstracts on treatment intensification options.

Beyond Basal Insulin in Type 2 Diabetes. from ADA Scientific Sessions

Insulin Degludec/Liraglutide vs. Insulin Glargine. Abstract link.

Patients with T2DM treated with insulin degludec/liraglutide have a greater chance of reaching glycemic targets.

Insulin degludec/liraglutide led to better glycemic control.

Faster-acting Insulin Aspart. Abstract link.

Faster-acting insulin aspart improves postprandial glycemic control in uncontrolled T2DM.

Faster aspart effectively improved 1-hour postprandial plasma glucose control.

Faster-acting Insulin vs. Basal Insulin. Abstract link.

Adding faster-acting insulin aspart to basal insulin significantly improved glycemic control.

Faster aspart in a basal-bonus regimen provided superior glycemic control versus basal insulin only.

Insulin Glargine/Lixisenatide vs. Insulin Glargine. Abstract link.

A fixed-ratio combination of insulin glargine/lixisenatide is more effective and safer than insulin glargine in patients with T2DM.

After a 6-week run-in phase, insulin glargine was introduced or optimized.

Glargine/lixisenatide showed superior glycemic control to insulin glargine.

PreviousNext

Related Content:

ADADiabetes
Exenatide Extended-Release Receives Historic FDA Approval for Use in Pediatric Type 2 Diabetes
Dapagliflozin Safe and Effective in Stage 4 Chronic Kidney Disease, DAPA-CKD Analysis Finds
FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy